Practice Variation on Antithrombotics in COVID-19

Status Completed

Clinical Trial Summary

Evidence suggests coronavirus disease 2019 (COVID-19) is associated with an increased incidence of thromboembolic manifestations. Various guidelines on managing antithrombotics in COVID-19 either provided conflicting guidance or unclear recommendations for post-discharge thromboprophylaxis. The investigators aim to collect the current practices in India among physicians on antithrombotic therapy for hospitalised patients with COVID-19 and after discharge from the hospital.

Clinical Trial Description

Immune dysregulation plays a crucial role in the development of severe coronavirus disease 2019 (COVID-19). The autopsy of lungs in deceased COVID-19 patients showed micro thrombosis and inflammatory infiltrates similar to acute respiratory distress syndrome (ARDS). Reports of increased incidence of arterial or venous thrombosis with COVID-19 made initial recommendations regarding using higher doses of anticoagulation. The markers of thrombosis like D-dimer, platelet count, fibrinogen are also increased in patients with COVID-19 along with other inflammatory markers. The pathophysiology of coagulopathy of COVID-19 is still under research. It is likely multi-factorial involving Inflammation, hypoxia, endothelial dysfunction, direct viral cytopathic effect, platelets and complement activation, derangement of the renin-angiotensin-aldosterone pathway. From the inception of the pandemic, the physicians started using various antithrombotic with higher than prophylactic doses to treat the prothrombotic state. In the absence of clear guidance with conflicting evidence, there is considerable variation in the practices of physicians managing COVID-19. The investigators are planning for a nationwide multicentre cross-sectional survey on understanding participating physicians practices on the choice of different antithrombotics available in India as of August 2021. The survey will have three sections: 1. Demographics 2. Antithrombotics in hospitalised patients 3. Antithrombotics after discharge from the hospital The investigators intend to involve 1000 physicians from different specialities with the help of the steering committee. ;

Study Design

Related Conditions & MeSH terms

Acute Lung Injury
COVID-19
COVID-19 Pneumonia
Pneumonia
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Severe Acute Respiratory Syndrome
Severe Acute Respiratory Syndrome (SARS) Pneumonia
Syndrome
Thrombosis

Clinical Trial Details

NCT number	NCT04998799
Study type	Observational
Source	NMC Specialty Hospital
Contact
Status	Completed
Phase
Start date	October 1, 2021
Completion date	November 10, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03826043` - THrombo-Embolic Event in Onco-hematology	N/A
Recruiting	`NCT04398628` - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed	`NCT05426564` - Exploratory Assessment of the Quantra® System in Adult ECMO Patients
Not yet recruiting	`NCT05830916` - Diagnostic Role of Antiphospholipid Antibodies and Microparticles in Immune Thrombocytopenic Patients With Thrombosis
Recruiting	`NCT02972385` - Pharmacogenomics of Warfarin in Hispanics and Latinos
Completed	`NCT02917213` - Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
Completed	`NCT02526628` - Thrombosis and Neurocognition in Klinefelter Syndrome
Completed	`NCT02439190` - CV004-007 Thrombosis Chamber Study	Phase 1
Completed	`NCT02341638` - Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects	Phase 1
Completed	`NCT01855516` - Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin	N/A
Unknown status	`NCT00983112` - Evicel Study on the Peri-operative Bleeding in Total Knee Prothesis Surgery	Phase 4
Completed	`NCT00412464` - Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis	Phase 1
Completed	`NCT00479362` - Anticoagulant Therapy During Pacemaker Implantation	Phase 4
Completed	`NCT00346424` - Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters	Phase 3
Terminated	`NCT00303420` - Alteplase for Blood Flow Restoration in Hemodialysis Catheters	Phase 4
Completed	`NCT00143715` - Oral Vitamin K for Warfarin Associated Coagulopathy	Phase 3
Completed	`NCT00039858` - Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin	Phase 4
Completed	`NCT00007410` - Genetic Architecture of Plasma T-PA and PAI-1	N/A
Completed	`NCT00000538` - Dietary Effects on Lipoproteins and Thrombogenic Activity	Phase 3
Completed	`NCT00005436` - Lupus Cohort--Thrombotic Events and Coronary Artery Disease	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.